GYBYS(SH:600332) Zheng Quan Shi Bao Wang·2025-12-29 03:25Group 1 - The core objective of Guangzhou Pharmaceutical Group is to establish an incubation platform and innovate the ecosystem, with an expected R&D investment of 10 billion to 15 billion yuan and industrial investment and acquisitions of 20 billion to 30 billion yuan during the 14th Five-Year Plan period [1] - The company aims to accelerate its transformation into a world-class pharmaceutical and health technology innovation enterprise by enhancing talent acquisition, building strong platforms, deepening ecosystems, expanding layouts, and optimizing incentives [1] - Guangzhou Pharmaceutical Group has become the first world Fortune 500 company primarily focused on traditional Chinese medicine, contributing significantly to the high-quality development of the biopharmaceutical industry in Guangdong Province [1] Group 2 - The 14th Five-Year Plan period is viewed as a golden window for Guangzhou Pharmaceutical Group to achieve leapfrog development, with a focus on transforming into a technology-driven and innovative enterprise group [2] - The company has appointed over 30 experts, including three academicians, to empower its innovation strategy, with notable appointments including Academician Rao Zihe as the head of the technology committee [2] - Guangzhou Pharmaceutical Group is actively integrating research resources and has established a comprehensive research and transformation support system, featuring seven major innovation research platforms [2] Group 3 - During the conference, Guangzhou Pharmaceutical Group signed over 20 cooperation projects, including strategic partnerships with Muen Bio and Huawei to accelerate digital development and application of microbiological technology [3] - Collaborations were also established with various universities and companies to enhance the synergy between industry, academia, and research [3]